nach oben

Pituitary

Erschienen in:

05.01.2018

Silent somatotroph pituitary adenomas: an update

verfasst von: Fabienne Langlois, Randall Woltjer, Justin S. Cetas, Maria Fleseriu

Erschienen in: Pituitary | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Silent growth hormone adenomas (SGHA) are a rare entity of non-functioning pituitary neuroendocrine tumors. Diagnosis is invariably made post-operatively of a tumor immunopositive for GH (and Pit-1 in selected cases) but without clinical acromegaly. Mainly young females are affected, and tumors are often uncovered by investigation for headaches or oligoamenorrhea. Integration of clinical, pathological and biochemical data is required for proper diagnosis. Beside normal IGF-1 levels, a third of SGHAs displays elevated GH levels and some will eventually progress to acromegaly. Almost two-thirds will be mixed GH-prolactin tumors and sparsely-granulated monohormonal GH tumors seems the more aggressive subtype. Recurrence and need for radiation is higher than other non-functioning tumors so close follow-up is warranted.

Molitch ME (2017) Diagnosis and treatment of pituitary adenomas: a review. JAMA 317(5):516–524CrossRefPubMed

Melmed S (2016) Pituitary medicine from discovery to patient-focused outcomes. J Clin Endocrinol Metab 101(3):769–777CrossRefPubMedPubMedCentral

Chanson P, Raverot G, Castinetti F, Cortet-Rudelli C, Galland F, Salenave S (2015) Management of clinically non-functioning pituitary adenoma. Ann Endocrinol (Paris) 76(3):239–247CrossRef

Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, Vance ML, Endocrine S (2011) Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(4):894–904CrossRefPubMedPubMedCentral

Aghi MK, Chen CC, Fleseriu M, Newman SA, Lucas JW, Kuo JS, Barkhoudarian G, Farrell CJ, Sheehan J, Ziu M, Dunn IF (2016) Congress of neurological surgeons systematic review and evidence-based guidelines on the management of patients with nonfunctioning pituitary adenomas: executive summary. Neurosurgery 79(4):521–523CrossRefPubMed

Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, Grossman A, Ikeda H, Inoshita N, Karavitaki N, Korbonits M, Laws ER Jr, Lopes MB, Maartens N, McCutcheon IE, Mete O, Nishioka H, Raverot G, Roncaroli F, Saeger W, Syro LV, Vasiljevic A, Villa C, Wierinckx A, Trouillas J, and the attendees of 14th Meeting of the International Pituitary Pathology Club AFN (2017) From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer 24(4):C5–C8CrossRef

Raverot G, Dantony E, Beauvy J, Vasiljevic A, Mikolasek S, Borson-Chazot F, Jouanneau E, Roy P, Trouillas J (2017) Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification. J Clin Endocrinol Metab 102(9):3368–3374CrossRefPubMed

Osamura RY (2017) Pathology of pituitary tumors update: with World Health Organization new classification 2017. AJSP: Rev Rep 22(4):189–195

Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134(4):521–535CrossRefPubMed

10.

Cooper O, Melmed S (2012) Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab 26(4):447–460CrossRefPubMedPubMedCentral

11.

Chinezu L, Vasiljevic A, Trouillas J, Lapoirie M, Jouanneau E, Raverot G (2017) Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature. Eur J Endocrinol 176(2):195–201CrossRefPubMed

12.

Wade AN, Baccon J, Grady MS, Judy KD, O’Rourke DM, Snyder PJ (2011) Clinically silent somatotroph adenomas are common. Eur J Endocrinol 165(1):39–44CrossRefPubMedPubMedCentral

13.

Langlois F, Lim DST, Varlamov E, Yedinak CG, Cetas JS, McCartney S, Dogan A, Fleseriu M (2017) Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience. Endocrine 58(3):528–534CrossRefPubMed

14.

Trouillas J, Sassolas G, Loras B, Velkeniers B, Raccurt M, Chotard L, Berthezène F, Tourniaire J, Girod C (1991) Somatotrpic adenomas without acromegaly. Pathol-Res Pract 187(8):943–949CrossRefPubMed

15.

Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156(2):203–216CrossRefPubMed

16.

Tourniaire J, Trouillas J, Chalendar D, Bonneton-Emptoz A, Goutelle A, Girod C (1985) Somatotropic adenoma manifested by galactorrhea without acromegaly. J Clin Endocrinol Metab 61(3):451–453CrossRefPubMed

17.

Batisse M, Raverot G, Maqdasy S, Durando X, Sturm N, Montoriol P-F, Kemeny JL, Chazal J, Trouillas J, Tauveron I (2013) Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide. Cancer Invest 31:190–196CrossRefPubMed

18.

Bengtsson D, Schrøder HD, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U, Rasmussen ÅK, Johannsson G, Hoybye C, van der Lely AJ, Petersson M, Ragnarsson O, Burman P (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab 100(4):1689–1698CrossRefPubMed

19.

Daems T, Verhelst J, Michotte A, Abrams P, Ridder D, Abs R (2009) Modification of hormonal secretion in clinically silent pituitary adenomas. Pituitary 12(1):80–86CrossRefPubMed

20.

Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, Young WF Jr (2009) Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol (Oxford) 71(1):92–99CrossRef

21.

Furuhata S, Kameya T, Otani M, Shimamoto Y, Asada H, Toya S (1991) Silent mixed growth hormone cell-prolactin cell pituitary adenoma. Endocr Pathol 2(4):230CrossRef

22.

Fusco A, Giampietro A, Bianchi A, Cimino V, Lugli F, Piacentini S, Lorusso M, Tofani A, Perotti G, Lauriola L, Anile C, Maira G, Pontecorvi A, De Marinis L (2012) Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study. Pituitary 15(4):571–578CrossRefPubMed

23.

Ghazi AA, Rotondo F, Kovacs K, Amirbaigloo A, Syro LV, Fathalla H, Di Ieva A, Cusimano MD (2015) Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature. Endocr Pathol 26(2):135–139CrossRefPubMed

24.

Horvath E, Kovacs K, Smyth HS, Cusimano M, Singer W (2005) Silent adenoma subtype 3 of the pituitary—immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 29(6):511–524CrossRefPubMed

25.

Kalavalapalli S, Reid H, Kane J, Buckler H, Trainer P, Heald AH (2007) Silent growth hormone secreting pituitary adenomas: IGF-1 is not sufficient to exclude growth hormone excess. Ann Clin Biochem 44(1):89–93CrossRefPubMed

26.

Kobayashi I, Oka H, Naritaka H, Sato Y, Fujii K, Kameya T (2002) Expression of Pit-1 and growth hormone-releasing hormone receptor mRNA in human pituitary adenomas: difference among functioning, silent, and other nonfunctioning adenomas. Endocr Pathol 13(2):83–98CrossRefPubMed

27.

Naritaka H, Kameya T, Sato Y, Furuhata S, Otani M, Kawase T (1999) Morphological characterization and subtyping of silent somatotroph adenomas. Pituitary 1(3):233–241CrossRefPubMed

28.

Neto L, Chimelli L, Da M. Pereira P, Gasparetto E, Bines J, Wildemberg L, Gadelha M (2013) The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma. Endocr Pract 19(6):e145–e149CrossRef

29.

Pestell R, Herington A, Best J, Boolell M, McKelvie P, Arnott R, Alford F (1991) Growth hormone excess and galactorrhoea without acromegalic features. Case reports. BJOG 98(1):92–97CrossRef

30.

Kovacs K, Lloyd R, Horvath E, Asa SL, Stefaneanu L, Killinger DW, Smyth HS (1989) Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization. Am J Pathol 134(2):345–353PubMedPubMedCentral

31.

Matsuno A, Ogino Y, Itoh J, Osamura RY, Nagashima T (2000) Detection of a silent pituitary somatotroph adenoma in a patient with amenorrhea and/or galactorrhea: paradoxical response of GH in TRH or GnRH provocation test. Endocr J 47(Suppl March):S105–S109CrossRefPubMed

32.

Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, Ezzat S, Asa SL (2016) Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol 29(2):131–142CrossRefPubMed

33.

Villa C, Lagonigro MS, Magri F, Koziak M, Jaffrain-Rea ML, Brauner R, Bouligand J, Junier MP, Di Rocco F, Sainte-Rose C, Beckers A, Roux FX, Daly AF, Chiovato L (2011) Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation. Endocr Relat Cancer 18(3):347–356CrossRefPubMed

34.

Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K, Sano T (2007) A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61(3):580–584CrossRefPubMed

35.

Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, Fukuhara N, Yamaguchi-Okada M, Takeuchi Y, Yamada S (2015) The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol 26(4):349–355CrossRefPubMed

36.

Klibanski A, Zervas NT, Kovacs K, Ridgway EC (1987) Clinically silent hypersecretion of growth hormone in patients with pituitary tumors. J Neurosurg 66(6):806–811CrossRefPubMed

37.

Yamada S, Sano T, Stefaneanu L, Kovacs K, Aiba T, Sawano S, Shishiba Y (1993) Endocrine and morphological study of a clinically silent somatotroph adenoma of the human pituitary. J Clin Endocrinol Metab 76(2):352–356PubMed

38.

Sakharova AA, Dimaraki EV, Chandler WF, Barkan AL (2005) Clinically silent somatotropinomas may be biochemically active. J Clin Endocrinol Metab 90(4):2117–2121CrossRefPubMed

39.

Kontogeorgos G (2005) Classification and pathology of pituitary tumors. Endocrine 28(1):27–35CrossRefPubMed

40.

Syro LV, Rotondo F, Serna CA, Ortiz LD, Kovacs K (2017) Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary. Pituitary 20(1):84–92CrossRefPubMed

41.

Sidhaye A, Burger PMD, Rigamonti D, Salvatori R (2005) Giant Somatotrophinoma without acromegalic features: more “quiet” than “silent”: case report. Neurosurgery 56(5):E1154PubMed

42.

Fleseriu M, Bodach ME, Tumialan LM, Bonert V, Oyesiku NM, Patil CG, Litvack Z, Aghi MK, Zada G (2016) Congress of neurological surgeons systematic review and evidence-based guideline for pretreatment endocrine evaluation of patients with nonfunctioning pituitary adenomas. Neurosurgery 79(4):E527–E529CrossRefPubMed

43.

Schilbach K, Strasburger CJ, Bidlingmaier M (2017) Biochemical investigations in diagnosis and follow up of acromegaly. Pituitary 20(1):33–45CrossRefPubMed

44.

Veldhuis JD, Roelfsema F, Keenan DM, Pincus S (2011) Gender, age, body mass index, and IGF-I individually and jointly determine distinct GH dynamics: analyses in one hundred healthy adults. J Clin Endocrinol Metab 96(1):115–121CrossRefPubMed

45.

Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine S (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951CrossRefPubMed

46.

Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, Samuels MH (2016) Hormonal Replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101(11):3888–3921CrossRefPubMed

47.

Mavromati M, Kuhn E, Agostini H, Brailly-Tabard S, Massart C, Piketty ML, Arnoux A, Young J, Souberbielle JC, Chanson P (2017) Classification of patients With GH disorders may vary according to the IGF-I assay. J Clin Endocrinol Metab 102(8):2844–2852CrossRefPubMed

48.

Freda PU (2009) Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxford) 71(2):166–170CrossRef

49.

Faje AT, Barkan AL (2010) Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 95(5):2486–2491CrossRefPubMedPubMedCentral

50.

Butz LB, Sullivan SE, Chandler WF, Barkan AL (2016) “Micromegaly”: an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era. Pituitary 19(6):547–551CrossRefPubMed

51.

Ribeiro-Oliveira A Jr, Faje AT, Barkan AL (2011) Limited utility of oral glucose tolerance test in biochemically active acromegaly. Eur J Endocrinol 164(1):17–22CrossRefPubMed

52.

Lania AG, Ferrero S, Pivonello R, Mantovani G, Peverelli E, Di Sarno A, Beck-Peccoz P, Spada A, Colao A (2010) Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J Clin Endocrinol Metab 95(1):13–17CrossRefPubMed

53.

Andersen M, Hagen C, Frystyk J, Schroeder HD, Hagen C (2003) Development of acromegaly in patients with prolactinomas. Eur J Endocrinol 149(1):17–22CrossRefPubMed

54.

Manuylova E, Calvi LM, Hastings C, Vates GE, Johnson MD, Cave WT Jr, Shafiq I (2016) Late presentation of acromegaly in medically controlled prolactinoma patients. Endocrinol Diabetes Metab Case Rep. https://doi.org/10.1530/EDM-16-0069 PubMedPubMedCentral

55.

Matsuno A, Sanno N, Tahara S, Teramoto A, Osamura RY, Wada H, Murakami M, Tanaka H, Nagashima T (1999) Silent somatotroph adenoma, detected by catalyzed signal amplification and non-radioisotopic in situ hybridization. Endocr J 46(Suppl):S81–S84CrossRefPubMed

56.

Birzniece V, Sata A, Sutanto S, Ho KKY (2010) Paracrine regulation of growth hormone secretion by estrogen in women. J Clin Endocrinol Metab 95(8):3771–3776CrossRefPubMed

57.

Ben-Jonathan N, Liby K, McFarland M, Zinger M (2002) Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab 13(6):245–250CrossRefPubMed

58.

Pagesy P, Li JY, Kujas M, Peillon F, Delalande O, Visot A, Derome P (1991) Apparently silent somatotroph adenomas. Pathol Res Pract 187(8):950–956CrossRefPubMed

59.

Hallengren E, Almgren P, Svensson M, Gallo W, Engstrom G, Persson M, Melander O (2017) Genetic determinants of growth hormone and GH-related phenotypes. BMC Genom 18(1):822CrossRef

60.

Leung K-C, Johannsson G, Leong GM, Ho KKY (2004) Estrogen regulation of growth hormone action. Endocr Rev 25(5):693–721CrossRefPubMed

61.

Duarte FH, Jallad RS, Bronstein MD (2016) Estrogens and selective estrogen receptor modulators in acromegaly. Endocrine 54(2):306–314CrossRefPubMed

62.

Brzana JA, Yedinak CG, Delashaw JB, Gultelkin HS, Cook D, Fleseriu M (2012) Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naive to medical therapy and radiation: what to follow, GH or IGF-1 values? Pituitary 15(4):562–570CrossRefPubMed

63.

Bianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A, De Marinis L (2009) Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 94(6):2015–2022CrossRefPubMed

64.

Boguszewski CL, Barbosa EJL, Svensson PA, Johannsson G, Glad CAM (2017) MECHANISMS IN ENDOCRINOLOGY: Clinical and pharmacogenetic aspects of the growth hormone receptor polymorphism. Eur J Endocrinol 177(6):R309–R321CrossRef

65.

Abe T, Taniyama M, Xu B, Ozawa H, Kawamura N, Shimazu M, Sasaki K, Izumiyama H, Kushima M, Kuwazawa J, Sano T, Matsumoto K (2001) Silent mixed corticotroph and somatotroph macroadenomas presenting with pituitary apoplexy. Acta Neuropathol 102(5):435–440PubMed

66.

Chinezu L, Jouanneau E, Vasiljevic A, Trouillas J, Raverot G (2013) Clinical case: Silent GH pituitary tumor: diagnostic and therapeutic challenges. Les adénomes hypophysaires somatotropes silencieux: défis thérapeutiques et diagnostiques, vol 74. Elsevier Masson, Toronto, pp. 491–495 (French)

Titel: Silent somatotroph pituitary adenomas: an update
verfasst von: Fabienne Langlois
Randall Woltjer
Justin S. Cetas
Maria Fleseriu
Publikationsdatum: 05.01.2018
Verlag: Springer US
Erschienen in: Pituitary / Ausgabe 2/2018
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-017-0858-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Silent somatotroph pituitary adenomas: an update

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Nierenultraschall: Tipps vom Profi

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Management of nonfunctioning pituitary tumors: radiotherapy

Histopathological classification of non-functioning pituitary neuroendocrine tumors

Management of nonfunctioning pituitary adenomas (NFAs): observation

Non-functioning pituitary adenomas, not all the same and certainly not boring!

Pathogenesis of non-functioning pituitary adenomas

Management of non-functioning pituitary adenomas: surgery

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Nierenultraschall: Tipps vom Profi

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Update Innere Medizin